Literature DB >> 6174458

Cyclosporin a permits the distinction between specific T and NK activity generated in a human MLC.

U Landegren, U Ramstedt, I Axberg, A Orn, H Wigzell.   

Abstract

Human lymphocytes, activated in mixed lymphocyte culture (MLC), express cytolytic activity against a range of target cell types. Cyclosporin A (CyA) efficiently prevents the development of cytotoxic T cells directed against target cells expressing the phenotype of the stimulator cells whilst not preventing an increase in natural killing (NK) activity measured against tumor targets. The drug was further shown not to influence the short-term induction of increased NK activity by interferon. Already established T killer cells are not sensitive to CyA. The drug thus seems to be selectively involved in the induction of immune responses requiring T-cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6174458     DOI: 10.1002/ijc.2910280611

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Membrane markers, target cell specificity, and sensitivity to biological response modifiers distinguish human natural cytotoxic from human natural killer cells.

Authors:  M Rola-Pleszczynski; H Lieu; A K Sullivan; M Girard
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

2.  Cyclosporin A inhibits lymphokine production but not the responses of macrophages to lymphokines.

Authors:  A W Thomson; D K Moon; C L Geczy; D S Nelson
Journal:  Immunology       Date:  1983-02       Impact factor: 7.397

3.  Effects of cyclosporin A on immunoglobulin production by EB virus stimulated lymphocytes.

Authors:  R S Pereira; A J Gear; C J Doré; A D Webster
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

Review 4.  Cyclosporine: immunology, toxicity and pharmacology in experimental animals.

Authors:  A W Thomson; P H Whiting; J G Simpson
Journal:  Agents Actions       Date:  1984-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.